GLP1_NEW
Exenatide extended release and dapagliflozin 2 to 10 mg injection once weekly
EXENER_SC_2-10MG_QW
Effects across outcomes
Bayesian random effects estimate against the comparator of each analysis (usually placebo), posterior median and 95% credible interval. Green: clearly better; red: clearly worse.
| Condition | Outcome | Window | Versus | Effect (95% CrI) | SUCRA |
|---|---|---|---|---|---|
| Overweight or obesity without diabetes (adults) | Systolic blood pressure change | weeks 20 to 40 (target week 26) | Placebo | MD -6.64 (-17.50 to 4.71) | 0.68 |
| Overweight or obesity without diabetes (adults) | Percent body weight change | weeks 20 to 40 (target week 26) | Placebo | MD -4.11 (-11.89 to 4.07) | 0.27 |
| Overweight or obesity without diabetes (adults) | Weight loss of 5 percent or more | weeks 20 to 40 (target week 26) | Placebo | OR 9.61 (1.08 to 93.80) | 0.50 |
| Overweight or obesity without diabetes (adults) | Weight loss of 10 percent or more | weeks 20 to 40 (target week 26) | Placebo | OR 7.23 (0.51 to 188) | 0.50 |
| Overweight or obesity without diabetes (adults) | Serious adverse events | longest follow-up | Placebo | HR 0.92 (0.06 to 13.55) | 0.55 |
| Overweight or obesity without diabetes (adults) | Discontinuation due to adverse events | longest follow-up | Placebo | HR 0.66 (0.09 to 4.01) | 0.73 |
| Overweight or obesity without diabetes (adults) | Nausea | longest follow-up | Placebo | HR 2.48 (0.71 to 10.97) | 0.62 |
| Overweight or obesity without diabetes (adults) | Vomiting | longest follow-up | Placebo | HR 2.70 (0.35 to 25.94) | 0.60 |
| Overweight or obesity without diabetes (adults) | Diarrhea | longest follow-up | Placebo | HR 0.99 (0.18 to 5.23) | 0.70 |
| Overweight or obesity without diabetes (adults) | Constipation | longest follow-up | Placebo | HR 1.71 (0.19 to 20.07) | 0.53 |